This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Eyetech Jumps on FDA OK

Wet AMD is caused by an overgrowth of new blood vessels in the macula, which is part of the retina and enables fine detailed vision. When these vessels leak blood or fluid, the macula bulges. That causes distorted vision and a decrease in central vision, often leading to legal blindness if the disease attacks both eyes.

(There is another type of age-related macular degeneration called dry AMD. It affects about 13.4 million Americans and is less severe than wet AMD. However, there is no treatment for dry AMD, and Macugen isn't approved for this disease.)

Macugen is the first in a new class of eye care drugs to inhibit the activity of vascular endothelial growth factor, or VEGF, a protein that plays a key role in developing the unwanted blood vessels. By blocking VEGF, the drug can stop the growth of runaway blood vessels before they can spread and leak. Macugen must be injected into the eye every six weeks.

Macugen also is the first therapy indicated for the treatment of all types of wet AMD. Until now, the only FDA-approved drug treatment was designed for one type of wet AMD that accounts for perhaps one-fourth of the affected patients.

This other treatment requires the intravenous injection of Visudyne, a drug made by QLT (QLTI) and Novartis (NVS - Get Report).The drug is administered every six months.

Visudyne chemically sensitizes the eye, which is then exposed to infrared light, also known as a cold laser. This therapy stops unwanted blood vessels from leaking. It doesn't restore lost vision and it doesn't stop the development of new blood vessels. Called photodynamic therapy, this treatment must be repeated every three to four months.

Another treatment involves using a thermal laser to cauterize the unwanted blood vessels in the eye. This laser leaves a permanent blind spot where AMD has already damaged the eye. Thermal lasers don't stop new blood vessels from developing; they don't restore lost sight. Visudyne and Macugen don't cause blind spots.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
MRVT $0.00 0.00%
IRIX $6.88 0.00%
NVS $95.36 -0.25%
PFE $31.89 -0.25%
QLTI $3.36 0.00%

Markets

Chart of I:DJI
DOW 16,374.76 +23.38 0.14%
S&P 500 1,951.13 +2.27 0.12%
NASDAQ 4,733.4970 -16.4820 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs